165 related articles for article (PubMed ID: 11602062)
1. Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
Kris-Etherton PM
Curr Atheroscler Rep; 2001 Nov; 3(6):435-6. PubMed ID: 11602062
[No Abstract] [Full Text] [Related]
2. The effects of simvastatin-niacin and antioxidant therapy on HDL.
Drown DJ
Prog Cardiovasc Nurs; 2002; 17(2):102-3. PubMed ID: 11986546
[No Abstract] [Full Text] [Related]
3. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
4. Trial clouds use of niacin with a statin.
Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
[No Abstract] [Full Text] [Related]
5. Effects of extended-release niacin on lipoprotein subclass distribution.
Morgan JM; Capuzzi DM; Baksh RI; Intenzo C; Carey CM; Reese D; Walker K
Am J Cardiol; 2003 Jun; 91(12):1432-6. PubMed ID: 12804729
[TBL] [Abstract][Full Text] [Related]
6. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Brown BG; Zhao XQ; Chait A; Fisher LD; Cheung MC; Morse JS; Dowdy AA; Marino EK; Bolson EL; Alaupovic P; Frohlich J; Albers JJ
N Engl J Med; 2001 Nov; 345(22):1583-92. PubMed ID: 11757504
[TBL] [Abstract][Full Text] [Related]
8. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
9. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
[TBL] [Abstract][Full Text] [Related]
10. Commentary: A new approach to atherogenic dyslipidemia.
Reasner CA
Postgrad Med; 2005 Apr; 117(4):13-6. PubMed ID: 15842128
[No Abstract] [Full Text] [Related]
11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
12. Niacin after coronary bypass grafting and for coronary disease prevention.
Parsons WB
Circulation; 2001 Jul; 104(2):E7. PubMed ID: 11447097
[No Abstract] [Full Text] [Related]
13. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
14. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
Sacks FM
Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
[TBL] [Abstract][Full Text] [Related]
15. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.
Khera AV; Patel PJ; Reilly MP; Rader DJ
J Am Coll Cardiol; 2013 Nov; 62(20):1909-10. PubMed ID: 23933538
[No Abstract] [Full Text] [Related]
16. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
17. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.
Cheung MC; Zhao XQ; Chait A; Albers JJ; Brown BG
Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1320-6. PubMed ID: 11498460
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
Ryan MJ; Gibson J; Simmons P; Stanek E
Am J Cardiol; 2003 Jun; 91(12):1427-31. PubMed ID: 12804728
[TBL] [Abstract][Full Text] [Related]
20. Getting more people on statins.
Roberts WC
Am J Cardiol; 2002 Sep; 90(6):683-5. PubMed ID: 12231110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
